Langerhans Cells Maintain Local Tissue Tolerance in a Model of Systemic Autoimmune Disease

J Immunol. 2015 Jul 15;195(2):464-76. doi: 10.4049/jimmunol.1402735. Epub 2015 Jun 12.

Abstract

Systemic autoimmune diseases such as lupus affect multiple organs, usually in a diverse fashion where only certain organs are affected in individual patients. It is unclear whether the "local" immune cells play a role in regulating tissue specificity in relation to disease heterogeneity in systemic autoimmune diseases. In this study, we used skin as a model to determine the role of tissue-resident dendritic cells (DCs) in local and systemic involvement within a systemic lupus disease model. Skin-resident DCs, namely, Langerhans cells (LCs), have been implicated in regulating tolerance or autoimmunity using elegant transgenic models, however, their role in local versus systemic immune regulation is unknown. We demonstrate that although lymphocytes from skin-draining lymph nodes of autoimmune-prone MRL/MpJ-Fas(lpr/lp) (r) (MRL-lpr) mice react spontaneously to a physiological skin self-Ag desmoglein-3, epicutaneous applications of desmoglein-3 induced tolerance that is dependent on LCs. Inducible ablation of LCs in adult preclinical MRL-lpr and MRL/MpJ-Fas(+/+) mice resulted in increased autoantibodies against skin Ags and markedly accelerated lupus dermatitis with increased local macrophage infiltration, but had no effect on systemic autoantibodies such as anti-dsDNA Abs or disease in other organs such as kidneys, lung, and liver. Furthermore, skin-draining lymph nodes of LC-ablated MRL-lpr mice had significantly fewer CD4(+) T cells producing anti-inflammatory cytokine IL-10 than LC-intact controls. These results indicate that a skin-resident DC population regulates local tolerance in systemic lupus and emphasize the importance of the local immune milieu in preventing tissue-specific autoimmunity, yet have no effect on systemic autoimmunity.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Animals
  • Autoantibodies / biosynthesis
  • Autoantigens / genetics
  • Autoantigens / immunology
  • Autoimmunity
  • CD4-Positive T-Lymphocytes / drug effects
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / pathology
  • Cell Movement
  • Desmoglein 3 / administration & dosage
  • Desmoglein 3 / genetics
  • Desmoglein 3 / immunology
  • Disease Models, Animal
  • Female
  • Gene Expression
  • Immune Tolerance*
  • Interleukin-10 / genetics
  • Interleukin-10 / immunology
  • Langerhans Cells / drug effects
  • Langerhans Cells / immunology*
  • Langerhans Cells / pathology
  • Lupus Erythematosus, Cutaneous / drug therapy
  • Lupus Erythematosus, Cutaneous / genetics
  • Lupus Erythematosus, Cutaneous / immunology*
  • Lupus Erythematosus, Cutaneous / pathology
  • Lymph Nodes / drug effects
  • Lymph Nodes / immunology
  • Lymph Nodes / pathology
  • Macrophages / drug effects
  • Macrophages / immunology
  • Macrophages / pathology
  • Mice
  • Mice, Inbred C57BL
  • Mice, Inbred MRL lpr
  • Skin / drug effects
  • Skin / immunology*
  • Skin / pathology

Substances

  • Autoantibodies
  • Autoantigens
  • Desmoglein 3
  • Dsg3 protein, mouse
  • IL10 protein, mouse
  • Interleukin-10